Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568997 · ClinicalTrials.gov registry record
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
A clinical trial of Atopic Dermatitis, sponsored by Bausch Health Americas.
- Active
- Registry status
- 8,000
- Enrollment target
- 1
- Study location
NCT00568997: Active study of Atopic Dermatitis, sponsored by Bausch Health Americas.
NCT00568997 is a study of Atopic Dermatitis that is active but no longer recruiting, run by Bausch Health Americas. The registered enrollment target is 8,000 participants, above the 556-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (1339% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568997, a study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Bausch Health Americas.
- ACTIVE NOT RECRUITING
- Registry status
- 8,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
Conditions Studied
Interventions
- DRUG Pimecrolimus
Study Locations (1)
Pennsylvania
- Registry - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2005-06-27 |
| Est. Completion | 2028-06 |
What the registry record for NCT00568997 still lists
NCT00568997 is an observational study that tracks outcomes without assigning an intervention. Its 8,000 participants enrollment target places it among the larger protocols in the corpus, above the 556-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (1339% higher).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Pimecrolimus is the first listed.
NCT00568997 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00568997 about?
NCT00568997 is a clinical study titled "10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus". This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
What is the current status of trial NCT00568997?
This trial is currently active not recruiting. The enrollment target is 8,000 participants. The study started on 2005-06-27. Estimated completion is 2028-06.
What conditions does trial NCT00568997 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT00568997?
The interventions under investigation include: Pimecrolimus (DRUG).
Who is sponsoring clinical trial NCT00568997?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00568997 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00568997's enrollment target sits among peer trials
8,000 3rd of 150 higher than 148 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00539162 · 8,000 participants · NA
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
- NCT00898638 · 8,000 participants
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
- NCT02240862 · 8,000 participants
The CREST-2 Registry
- NCT03072927 · 8,000 participants
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI